The immunogenicity and durability of genetic vaccines are influenced by the composition of gene inserts and choice of delivery vector. DNA vectors are a promising vaccine approach showing efficacy when combined in prime-boost regimens with recombinant protein or viral vectors, but they have shown limited comparative efficacy as a stand-alone platform in primates, due possibly to suboptimal gene expression or cell targeting. Here, regimens using DNA plasmids modified for optimal antigen expression and recombinant adenovirus (rAd) vectors, all encoding the glycoprotein (GP) gene from Angola Marburg virus (MARV), were compared for their ability to provide immune protection against lethal MARV Angola infection. Heterologous DNA-GP/rAd5-GP prime-boost and single-modality rAd5-GP, as well as the DNA-GP-only vaccine, prevented death in all vaccinated subjects after challenge with a lethal dose of MARV Angola. The DNA/DNA vaccine induced humoral responses comparable to those induced by a single inoculation with rAd5-GP, as well as CD4(+) and CD8(+) cellular immune responses, with skewing toward CD4(+) T-cell activity against MARV GP. Vaccine regimens containing rAd-GP, alone or as a boost, exhibited cellular responses with CD8(+) T-cell dominance. Across vaccine groups, CD8(+) T-cell subset dominance comprising cells exhibiting a tumor necrosis factor alpha (TNF-alpha) and gamma interferon (IFN-gamma) double-positive functional phenotype was associated with an absence or low frequency of clinical symptoms, suggesting that both the magnitude and functional phenotype of CD8(+) T cells may determine vaccine efficacy against infection by MARV Angola.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2937810PMC
http://dx.doi.org/10.1128/JVI.00594-10DOI Listing

Publication Analysis

Top Keywords

marv angola
12
genetic vaccines
8
angola marburg
8
marburg virus
8
rad5-gp well
8
cd8+ t-cell
8
functional phenotype
8
vaccine
6
angola
5
marv
5

Similar Publications

Virus Stability on Surfaces, in Bodily Fluids, in Wastewater and Different Environmental Conditions.

Methods Mol Biol

November 2024

Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.

Information concerning the fundamental properties of a pathogen is essential at the beginning of an outbreak. Often, the fundamental properties of an emerging virus are unknown because the virus is new, as in the recent SARS-CoV-2 pandemic, or because the properties have not been investigated, as was the case during the West African Ebola virus epidemic and the Marburg virus epidemics in Angola and the Democratic Republic of the Congo. The amount of time that a virus can remain viable under various conditions is one of these fundamental properties.

View Article and Find Full Text PDF

Evaluation of Vaccines and Therapeutics Against Marburg Virus in Nonhuman Primate Models.

Methods Mol Biol

November 2024

Galveston National Laboratory and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.

Marburg virus (MARV) has caused sporadic outbreaks of severe hemorrhagic fever in Africa in humans and nonhuman primates (NHPs) and has the potential to be used as a biological weapon. Currently, there are no licensed vaccines or therapeutics to respond to outbreaks or deliberate misuse. Vaccine and therapeutic efficacy testing against MARV requires animal models that accurately mimic human disease.

View Article and Find Full Text PDF

Evaluating Countermeasures Against Marburg Virus Using a Mouse Model.

Methods Mol Biol

November 2024

Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.

Animal models are key tools for understanding Marburg virus (MARV) pathogenesis and evaluating novel countermeasures. Rodents, in particular, are useful model systems because they are inexpensive and easy to house and handle in maximum containment laboratories. Unfortunately, wild-type MARV, like other filoviruses, does not cause disease in immune-competent rodents and must first be adapted to the rodent host, typically through serial passaging.

View Article and Find Full Text PDF

Vaccine Platform Comparison: Protective Efficacy against Lethal Marburg Virus Challenge in the Hamster Model.

Int J Mol Sci

August 2024

Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.

Marburg virus (MARV), a filovirus, was first identified in 1967 in Marburg, Germany, and Belgrade, former Yugoslavia. Since then, MARV has caused sporadic outbreaks of human disease with high case fatality rates in parts of Africa, with the largest outbreak occurring in 2004/05 in Angola. From 2021 to 2023, MARV outbreaks occurred in Guinea, Ghana, New Guinea, and Tanzania, emphasizing the expansion of its endemic area into new geographical regions.

View Article and Find Full Text PDF

Transcriptional profiling of immune responses in NHPs after low-dose, VSV-based vaccination against Marburg virus.

Emerg Microbes Infect

December 2023

Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.

Infection with Marburg virus (MARV), the causative agent of Marburg virus disease (MVD), results in haemorrhagic disease and high case fatality rates (>40%) in humans. Despite its public health relevance, there are no licensed vaccines or therapeutics to prevent or treat MVD. A vesicular stomatitis virus (VSV)-based vaccine expressing the MARV glycoprotein (VSV-MARV) is currently in clinical development.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!